ISB 1442 not checked

Ichnos Sciences SA

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“ISB 1442 SC injection dose regimen at RP2D until participants experience disease progression or unacceptable toxicity, or until any other discontinuation criterion is met”In the company’s words, NCT05427812 on ClinicalTrials.gov
Tested for
Relapsed/Refractory Multiple Myeloma
Main trialPhase 1/2
“This study is a first-in-human, Phase 1/2, open label study that will evaluate safety and efficacy of ISB 1442 in relapsed/refractory multiple myeloma (R/R MM).”In the company’s words, NCT05427812 on ClinicalTrials.gov

Other drugs for Relapsed/Refractory Multiple Myeloma

All 133 drugs for Relapsed/Refractory Multiple Myeloma

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Terminated 19 Nov 2024 Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow ISB 1442

Following is part of Solo: you see every change to ISB 1442 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in